Navann Ty
Stock Analyst at Exane BNP Paribas
(2.88)
# 1,716
Out of 4,974 analysts
26
Total ratings
64.29%
Success rate
26.02%
Average return
Main Sectors:
Stocks Rated by Navann Ty
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KVUE Kenvue | Initiates: Neutral | $28 | $18.62 | +50.38% | 1 | May 30, 2023 | |
| ALKS Alkermes | Maintains: Neutral | $22 → $26 | $29.94 | -13.16% | 10 | Mar 22, 2022 | |
| VTRS Viatris | Maintains: Neutral | $16 → $11 | $10.50 | +4.76% | 2 | Mar 10, 2022 | |
| ZTS Zoetis | Maintains: Neutral | $184 → $232 | $153.32 | +51.32% | 4 | Dec 20, 2021 | |
| JAZZ Jazz Pharmaceuticals | Initiates: Buy | $200 | $129.50 | +54.44% | 7 | Oct 5, 2021 | |
| OGN Organon & Co. | Initiates: Buy | $35 | $10.38 | +237.19% | 2 | Jul 23, 2021 |
Kenvue
May 30, 2023
Initiates: Neutral
Price Target: $28
Current: $18.62
Upside: +50.38%
Alkermes
Mar 22, 2022
Maintains: Neutral
Price Target: $22 → $26
Current: $29.94
Upside: -13.16%
Viatris
Mar 10, 2022
Maintains: Neutral
Price Target: $16 → $11
Current: $10.50
Upside: +4.76%
Zoetis
Dec 20, 2021
Maintains: Neutral
Price Target: $184 → $232
Current: $153.32
Upside: +51.32%
Jazz Pharmaceuticals
Oct 5, 2021
Initiates: Buy
Price Target: $200
Current: $129.50
Upside: +54.44%
Organon & Co.
Jul 23, 2021
Initiates: Buy
Price Target: $35
Current: $10.38
Upside: +237.19%